Cohort study reveals statin use improved overall survival in prostate cancer patients on apalutamide, suggesting careful monitoring for cardiac events.
Key Points
Statin exposure was associated with superior overall survival in patients treated with apalutamide, indicating its potential benefit in advanced prostate cancer.
Patients treated with apalutamide and using statins showed a hazard ratio of 0.53 for overall survival, highlighting a significant improvement in outcomes.
Incorporating individual patient data from two randomized clinical trials, the analysis used advanced Cox proportional hazard regression for accurate risk assessment.
Statin use in these patients is multifaceted; while improving survival, it also presents a higher risk of significant cardiac adverse events.